Clinical trials: Cancer, Breast
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Breast Cancer, Sentinel Lymph Node
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
The purpose of this study is to compare the effectiveness four different pain treatments for the injection of radioactive tracer that women with breast cancer receive for sentinel lymph node biopsies.
- Conditions
- Breast Cancer, Sentinel Lymph Node, Breast Neoplasms, Breast Cancer Female
- Trial name
- NCT04822597
- Testing
- Lidocaine patch, Buzzy(R), Ice pack
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer, HER2-positive Breast Cancer
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
This is an open-label, Phase 2 study to evaluate preliminary anti-tumor activity, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BDC-1001 administered as a single agent and in…
- Trial name
- NCT05954143
- Testing
- BDC-1001, Pertuzumab
- Where
- 4 sites in United States, Spain
- Volunteers
- 11 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Colonic Neoplasms, Breast Neoplasms
End-of-Life Care for African Americans
Racial differences in health care are documented across the health care continuum and persist in aging and end-of-life (EOL) care.
- Conditions
- Colonic Neoplasms, Breast Neoplasms, Lung Neoplasms
- Trial name
- NCT02320123
- Testing
- Educational DVD
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Early Stage Breast Cancer
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
This research study is testing the safety and feasibility of delivering the 4 cycles of 'dose-dense' paclitaxel without the use of Neulasta (Pegfilgrastim) as a Granulocyte Colony-stimulating Factor (G-CSF) support.
- Trial name
- NCT02698891
- Testing
- Paclitaxel, Neulasta
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Neoplasm Metastasis
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Primary Objectives: 1. To identify the optimal dose and pharmacokinetics of RAD001 in combination with trastuzumab in a Phase I trial 2.
- Trial name
- NCT00317720
- Testing
- Trastuzumab, RAD001
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Gastric Cancer
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
This multicenter study will assess the maximum tolerated dose (MTD) of capecitabine in combination with Kadcyla (trastuzumab emtansine) in participants with HER2-positive mBC or HER2-positive LA/mGC using a Phase 1 design…
- Trial name
- TRAXHER2 (NCT01702558)
- Testing
- Capecitabine, Trastuzumab emtansine (T-DM1)
- Where
- 40 sites in Argentina, Brazil and 10 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients…
- Trial name
- @FAME (NCT00357110)
- Testing
- Fulvestrant, Anastrozole
- Where
- 25 sites in Austria, Germany and 1 more
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Breast Cancer, Breast Neoplasms
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
This is a Phase II, randomized, open-label trial to evaluate the clinical and immunologic activity of pembrolizumab plus chemotherapy when combined with various immunotherapy induction regimens as neoadjuvant therapy for triple…
- Trial name
- NCT04373031
- Testing
- Pembrolizumab, IRX 2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Providence Health & Services
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer
Ruxolitinib in Patients With Breast Cancer
Ruxolitinib is a drug which blocks the Janus tyrosine Kinase (JAK) signaling pathway. It is thought that this pathway might be important in certain types of breast cancer, and that blocking this pathway might lead to anti-cancer…
- Trial name
- NCT01562873
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes
Currently, breast cancer patients who are treated with neoadjuvant chemotherapy (NAC) before surgery may have a biopsy clip placed in the lymph node at the time of or shortly after percutaneous biopsy.
- Trial name
- NCT03718455
- Testing
- Axillary Magseed
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Breast Cancer, Axillary Lymph Node Dissection
Upper Extremity Lymphatic Mapping for Breast Cancer Patients
This study is being done to see if lymph nodes that drain the arm also drain the breast. An axillary lymph node dissection removes lymph nodes under the arm.
- Trial name
- NCT00717886
- Testing
- isosulfan blue dye
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
This is a two-part study of pembrolizumab monotherapy in participants with metastatic triple-negative breast cancer (mTNBC). Part 1 of the study will examine the efficacy and safety of pembrolizumab monotherapy as first line or…
- Trial name
- NCT02447003
- Testing
- Pembrolizumab
- Volunteers
- 254 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphedema, Surgery
Intraoperative Evaluation of Axillary Lymphatics
This study will assess the feasibility of using the OnLume Imaging System for fluorescence-guided surgery along with indocyanine green (ICG) dye in the operating room for the axillary reverse mapping (ARM) procedure in women with…
- Conditions
- Lymphedema, Surgery, Breast Cancer
- Trial name
- NCT05094102
- Testing
- OnLume Imaging System, Indocyanine green
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT
The purpose of this study is to evaluate the role of technologist-performed whole breast ultrasound for detecting breast cancer in the screening population of women with dense breasts.
- Trial name
- DBTUST (NCT02643966)
- Testing
- Whole breast ultrasound
- Where
- 2 sites in United States
- Volunteers
- 6,266 people, healthy volunteers welcome
- Sponsor
- Wendie Berg
Metastatic Breast Cancer
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2- positive metastatic breast cancers
- Trial name
- PANACEA (NCT02129556)
- Testing
- MK-3475
- Where
- 11 sites in Australia, Austria and 3 more
- Volunteers
- 58 people
- Sponsor
- ETOP IBCSG Partners Foundation
Estrogen Receptor Negative, HER2/Neu Negative
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
This phase I/IB trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer
- Trial name
- NCT02120469
- Testing
- everolimus, eribulin mesylate, pharmacological study
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.